Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID

SeptiCyte® RAPID can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis Commercialization of SeptiCyte® to triage COVID-19 patients will be the focus of Biocartis partnership inEurope SEATTLE and BRISBANE, Australia, ...